Company intelligence / Profile preview

TriMix Laboratories

Boca Raton, Florida, United States

Ownership: Private
Development stage: Other

Overview

TriMix Laboratories develops TriMix-gel, a needle-free topical gel formulation of trimix (prostaglandin, papaverine, phentolamine) for erectile dysfunction treatment, as an alternative to injections for patients failing PDE5 inhibitors like Viagra. Clinical data shows 40% success rate in achieving erections sufficient for intercourse in prior PDE5 failures[1][2][7].

Therapeutic areas: Men's Health
Modalities: Small molecule
Industry: Biotech

Partnerships

KRS Global Biotechnology

Beyond the preview

Go deeper on TriMix Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TriMix Laboratories.

Explore the full profile